Rheumatoid Arthritis Clinical Trial
— VEDERAOfficial title:
A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early Versus Delayed Etanercept in Patients With Rheumatoid Arthritis
NCT number | NCT02433184 |
Other study ID # | RR10/9592 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | July 2011 |
Est. completion date | July 2019 |
Verified date | September 2019 |
Source | University of Leeds |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main aim of the study is to determine whether TNFi instituted as first-line therapy in early RA confers better outcomes (clinical, structural and immunological) compared to delayed TNFi start; implying particular dominance of TNF in early disease, a changing role of TNF with disease duration and hence, confirmation of a biological window of opportunity.
Status | Completed |
Enrollment | 120 |
Est. completion date | July 2019 |
Est. primary completion date | August 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Male and female patients aged between 18 and 80 years. - Diagnosis of rheumatoid arthritis (new 2010 ACR/EULAR RA classification criteria). - Symptom onset within the preceding 12 months. - Patients with active RA at baseline: clinical evidence of synovitis (or imaging evidence of synovitis in cases of uncertainty/subclinical disease) in hand and/or wrist joints evaluable by ultrasound and MRI, and DAS28-ESR>3.2. - Seropositivity for anti-citrullinated peptide antibody (ACPA) and/or rheumatoid factor. If ACPA and rheumatoid factor are both negative, presence of power Doppler in at least 1 joint on ultrasound imaging. - DMARD-naive (with the exception of previous exposure to hydroxychloroquine for an indication other than RA). - All male and female subjects biologically capable of having children must agree to use a reliable method of contraception for the duration of the study and 24 weeks after the end of the study period. Acceptable methods of contraception are surgical sterilisation, oral, implantable or injectable hormonal methods, intrauterine devices or barrier contraceptives. Exclusion Criteria: - Previous treatment with DMARDs for the management of RA. - Intramuscular or intra-articular (of non-target joint) corticosteroid within 28 days of the screening visit; intra-articular steroid of the chosen target joint within 12 weeks of screening. - Oral steroid of greater than 10mg prednisolone daily, or change in oral steroid dose within 28 days of study drug initiation at the baseline visit. - Use (including use as required) of more than one NSAID, change in NSAID or change in dose of NSAID within 28 days of the baseline visit. - Contraindications to MRI (e.g. pacemaker) or unable or unwilling to attend for all imaging assessments. In patients with previous penetrating trauma to the eye, or patients at high risk of previous metal foreign body injury to the eye (e.g. welding), skull x-ray will be performed; these patients may be included in the absence of residual metal fragments on x-ray. - Pregnancy or breastfeeding. - Other contraindications to TNFi as determined by local prescribing guidelines and physician discretion, including: - Active infection, open leg ulcers, previously infected prosthetic joint (unless completely removed), septic arthritis in last year, HIV, Hepatitis B or Hepatitis C carriers, previous malignancy within 10 years (except basal cell carcinoma), severe heart failure (New York Heart Association grade 3 or more), any history of demyelinating disease, uncontrolled diabetes, pulmonary fibrosis, bronchiectasis, previous PUVA therapy (of >1000 Joules), history of TB or evidence of latent TB on chest x-ray/TB testing (in the latter event, a patient may be included if treated with isoniazid and pyridoxine one month before starting the study and for a further 6 months whilst on study treatments). - History of other significant medical conditions, including: - Severe pulmonary disease, defined as requiring previous hospital admission or supplemental oxygen. - Active or severe cardiovascular disease: uncontrolled hypertension, myocardial infarction within 12 months of screening, unstable angina within 6 months of screening. - Other immunodeficiency disorders. - Connective tissue diseases, e.g. primary Sjogren's syndrome, systemic sclerosis, systemic lupus erythematosus, polymyositis. - Psoriasis. - Renal impairment (creatinine = 175µmol/L). - Blood disorders: neutropenia (neutrophils < 2.0 x 109/L), thrombocytopenia (platelets < 125 x 109/L), or anaemia (haemoglobin < 8 g/dL). - Abnormal liver function (alanine transaminase, ALT > 3 x upper limit of normal). - Planned surgery within the study period which is expected to require omission of any study medication of 28 days or more. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital | Leeds | West Yorkshire |
Lead Sponsor | Collaborator |
---|---|
University of Leeds |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical remission | Proportion of patients that achieve clinical remission (Disease activity Score, DAS28 <2.6) at 48 weeks, following either treatment strategy. | 48 weeks | |
Secondary | Change in MRI synovitis | Change in MRI synovitis between baseline and 48 weeks. | baseline and week 48 | |
Secondary | CDAI (clinical disease activity index) | Change in CDAI score from baseline at weeks 12, 24, 48 and 96 | weeks 12, 24, 48 and 96 | |
Secondary | SDAI (simplified disease activity index) | Change in SDAI score from baseline at weeks 12, 24, 36 & 48. | weeks 12, 24, 48 and 96 | |
Secondary | ACR(American College of Rheumatology) response scores | ACR response score from baseline at weeks 12, 24, 48 and 96 | weeks 12, 24, 48 and 96 | |
Secondary | EULAR(European League Against Rheumatism)response criteria | EULAR response score from baseline | weeks 12, 24, 48 and 96 | |
Secondary | Physical function, assessed by HAQ(health assessment questionnaire) | weeks 12, 24, 48 and 96 | ||
Secondary | Quality of life scores assessed by RA-QoL(RA quality of life questionnaire) | weeks 12, 24, 48 and 96 | ||
Secondary | Work instability, assessed by RA-WIS(RA work instability questionnaire) | weeks 12, 24, 48 and 96 | ||
Secondary | HRUS (High Resolution Ultrasound) | Change in HRUS from baseline | weeks 0, 12, 24 and 48 | |
Secondary | Radiographic scores | Change in joint damage assessed by modified Sharp score. | weeks 48 and 96 | |
Secondary | Immunological parameters in blood sample | Change in immunological markers of inflammation between baseline and weeks 12, 24 and 48. | weeks 0, 12, 24 and 48 | |
Secondary | Immunological parameters in synovial tissue | Change in immunological markers of inflammation between baseline and weeks 24 and 48. | weeks 0, 24, +/- 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |